|
Video: What is a Stock Split?
|
|
Xenetic Biosciences is a biopharmaceutical company. Co.'s drug candidates pipeline include: XCART, which is a CAR T cell platform technology engineered to target patient-specific tumor neoantigens; ErepoXen (polysialylated erythropoietin), which uses Co.'s PolyXen platform technology for the treatment of anemia in chronic kidney disease patients; XBIO-101, which is an internal candidate with orphan drug designation from the U.S. Food and Drug Administration for the potential treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy; and OncoHist, which utilizes the properties of modified human histone H1.3 for targeted cell killing. According to our XBIO split history records, Xenetic Biosciences has had 2 splits. | |
|
Xenetic Biosciences (XBIO) has 2 splits in our XBIO split history database. The first split for XBIO took place on June 25, 2019. This was a 1 for 12 reverse split, meaning for each 12 shares of XBIO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 83.3333333333333 share position following the split. XBIO's second split took place on May 15, 2023. This was a 1 for 10 reverse split, meaning for each 10 shares of XBIO owned pre-split, the shareholder now owned 1 share. For example, a 83.3333333333333 share position pre-split, became a 8.33333333333333 share position following the split.
When a company such as Xenetic Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the XBIO split history from start to finish, an original position size of 1000 shares would have turned into 8.33333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Xenetic Biosciences shares, starting with a $10,000 purchase of XBIO, presented on a split-history-adjusted basis factoring in the complete XBIO split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/30/2016 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$612.00 |
|
End price/share: |
$3.98 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.35% |
|
Average Annual Total Return: |
-47.80% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$65.06 |
|
Years: |
7.75 |
|
|
|
Date |
Ratio |
06/25/2019 | 1 for 12 | 05/15/2023 | 1 for 10 |
|
|